Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | RORB | Q92753 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 8/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28759927 | 0.89 | ERN1 (0.46) | ERN1MAPTCNR2POLB | |
| SCHEMBL2478195 | 0.86 | RORC (0.50) | RORCRORBPTPN5MAPTCNR2 | |
| SCHEMBL30679626 | 0.83 | RORC (0.45) | RORCRORBPTPN5ERN1MAPT | |
| SCHEMBL15675097 | 0.82 | PTPN5 (0.43) | RORCRORBPTPN5ALOX15ALOX12 | |
| SCHEMBL30861657 | 0.82 | RORB (0.50) | RORCRORBPTPN5MAPTPOLB | |
| SCHEMBL28839039 | 0.82 | RORC (0.44) | RORCRORBPTPN5ALOX15ALOX12 | |
| SCHEMBL8846192 | 0.82 | MAPT (0.51) | PTPN5ALOX15ALOX12ERN1MAPT | |
| SCHEMBL18003529 | 0.82 | RORC (0.44) | RORCRORBMAPTPOLBTOP2A | |
| SCHEMBL8881894 | 0.82 | RORB (0.44) | RORCRORBMAPTPOLBAKR1C3 | |
| SCHEMBL1802275 | 0.81 | MAPT (0.46) | RORCRORBPTPN5ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106633020-B | A kind of big steric hindrance salicylic alidehyde imine zinc class 6-caprolactone ring-opening polymerization catalyst and its preparation method and application | 常州大学 | 2019-03-22 | — | — | CN | disclosed |
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | RORC 2764/4885RORB 3583/4885PTPN5 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.